JP2017516781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516781A5 JP2017516781A5 JP2016569405A JP2016569405A JP2017516781A5 JP 2017516781 A5 JP2017516781 A5 JP 2017516781A5 JP 2016569405 A JP2016569405 A JP 2016569405A JP 2016569405 A JP2016569405 A JP 2016569405A JP 2017516781 A5 JP2017516781 A5 JP 2017516781A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- treatment
- acceptable salt
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 22
- 208000003174 Brain Neoplasms Diseases 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 14
- 238000004519 manufacturing process Methods 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 8
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 6
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 6
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 6
- 230000001394 metastastic effect Effects 0.000 claims 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims 6
- 238000001959 radiotherapy Methods 0.000 claims 4
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 3
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 claims 3
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 206010050017 Lung cancer metastatic Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 230000003140 astrocytic effect Effects 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229940097042 glucuronate Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 claims 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical group FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 1
- 229960000572 olaparib Drugs 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- -1 salt compound Chemical class 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 0 CCCCCN(CC*)c1ccc2[n](C)c(CCCCCCC(NO)=O)nc2c1 Chemical compound CCCCCN(CC*)c1ccc2[n](C)c(CCCCCCC(NO)=O)nc2c1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1409471.8A GB201409471D0 (en) | 2014-05-28 | 2014-05-28 | Pharmaceutical composition |
| GB1409471.8 | 2014-05-28 | ||
| PCT/EP2015/056667 WO2015180865A1 (en) | 2014-05-28 | 2015-03-26 | Compounds for treating brain cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516781A JP2017516781A (ja) | 2017-06-22 |
| JP2017516781A5 true JP2017516781A5 (enExample) | 2018-05-10 |
| JP6553092B2 JP6553092B2 (ja) | 2019-07-31 |
Family
ID=51177574
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569405A Active JP6553092B2 (ja) | 2014-05-28 | 2015-03-26 | 脳がんを治療するための化合物 |
| JP2016569589A Pending JP2017518291A (ja) | 2014-05-28 | 2015-05-26 | 癌を処置するための医薬組合せ |
| JP2020215170A Active JP7274450B2 (ja) | 2014-05-28 | 2020-12-24 | 癌を処置するための医薬組合せ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569589A Pending JP2017518291A (ja) | 2014-05-28 | 2015-05-26 | 癌を処置するための医薬組合せ |
| JP2020215170A Active JP7274450B2 (ja) | 2014-05-28 | 2020-12-24 | 癌を処置するための医薬組合せ |
Country Status (21)
| Country | Link |
|---|---|
| US (10) | US11419853B2 (enExample) |
| EP (4) | EP3148529B1 (enExample) |
| JP (3) | JP6553092B2 (enExample) |
| KR (2) | KR102383794B1 (enExample) |
| CN (3) | CN106659712A (enExample) |
| AU (2) | AU2015266342B2 (enExample) |
| BR (2) | BR112016027048B1 (enExample) |
| CA (2) | CA2950374C (enExample) |
| DK (1) | DK3148529T3 (enExample) |
| EA (2) | EA037057B1 (enExample) |
| ES (2) | ES2897727T3 (enExample) |
| GB (1) | GB201409471D0 (enExample) |
| IL (2) | IL249231B (enExample) |
| MX (2) | MX376193B (enExample) |
| PH (2) | PH12016502354A1 (enExample) |
| PT (1) | PT3148529T (enExample) |
| SG (4) | SG11201609365UA (enExample) |
| TW (1) | TWI724990B (enExample) |
| UA (2) | UA121311C2 (enExample) |
| WO (2) | WO2015180865A1 (enExample) |
| ZA (2) | ZA201607384B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201601773D0 (en) | 2016-02-01 | 2016-03-16 | Renishaw Plc | Method |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018068832A1 (en) | 2016-10-11 | 2018-04-19 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| TWI651088B (zh) | 2017-03-23 | 2019-02-21 | 國立東華大學 | 用於治療癌症的Scalarane二倍半萜類、醫藥組合物及拓樸異構酶II與 Hsp90抑制劑及其用途與製備方法 |
| GB201709402D0 (en) * | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709403D0 (en) * | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709405D0 (en) * | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| BR112020005079A2 (pt) * | 2017-09-14 | 2020-09-15 | Glaxosmithkline Intellectual Property Development Limited | tratamento de combinação para câncer |
| EP3897626B1 (en) * | 2018-12-18 | 2025-09-10 | Mundipharma International Corporation Limited | Tinostamustine for treating multiple myeloma |
| CN112023022A (zh) * | 2020-10-20 | 2020-12-04 | 澳门大学 | 卡非佐米在制备治疗抗药肿瘤的药物中的新的应用 |
| JP7600020B2 (ja) | 2021-03-31 | 2024-12-16 | 株式会社小糸製作所 | 画像投影装置 |
| KR20250054737A (ko) * | 2023-10-16 | 2025-04-23 | 주식회사 아스트로젠 | 신규한 분자 접착제의 용도 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE34727C (de) | Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue | Verfahren zur direkten Gewinnung metallischen Bleis | ||
| DD34727A1 (de) | 1963-12-21 | 1964-12-28 | Dietrich Krebs | Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| GB8926612D0 (en) | 1989-11-24 | 1990-01-17 | Erba Farmitalia | Pharmaceutical compositions |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| US5882941A (en) | 1994-05-04 | 1999-03-16 | Massachusette Institute Of Technology | Programmable genotoxic agents and uses therefor |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| ES2210769T3 (es) | 1997-06-13 | 2004-07-01 | Cydex Inc. | Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua. |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6214852B1 (en) | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
| US20020076409A1 (en) | 2000-07-12 | 2002-06-20 | March Carl J. | Method for treating cancer |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| CA2423868C (en) | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| WO2002055017A2 (en) | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
| CN1764648A (zh) | 2003-01-13 | 2006-04-26 | 安斯泰来制药有限公司 | 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物 |
| EP1599449A2 (en) | 2003-02-25 | 2005-11-30 | TopoTarget UK Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors |
| US20060270730A1 (en) | 2003-08-07 | 2006-11-30 | Andreas Katopodis | Histone deacetylase inhibitors as immunosuppressants |
| US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| CA2561617A1 (en) | 2004-04-05 | 2005-10-20 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
| WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| SI1901729T1 (sl) | 2005-05-13 | 2012-05-31 | Topotarget Uk Ltd | Farmacevtske formulacije HDAC inhibitorjev |
| US7399956B2 (en) | 2005-11-28 | 2008-07-15 | Avago Technologies Ecbuip Pte Ltd | Optical encoder with sinusoidal photodetector output signal |
| NZ575394A (en) | 2006-10-20 | 2012-01-12 | Icos Corp | Compositions of chk1 inhibitors and cyclodextrin |
| GB0621160D0 (en) | 2006-10-24 | 2006-12-06 | Imp College Innovations Ltd | Compounds and uses thereof |
| WO2008063644A1 (en) | 2006-11-20 | 2008-05-29 | Cephalon, Inc. | Method of radio-sensitizing tumors using a radio-sensitizing agent |
| JP2010512407A (ja) * | 2006-12-11 | 2010-04-22 | ジェネンテック インコーポレイテッド | 新生物を処置するための組成物および方法 |
| CN101084876A (zh) | 2007-07-11 | 2007-12-12 | 济南康泉医药科技有限公司 | 一种含苯达莫司汀的抗癌组合物 |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| WO2009067453A1 (en) | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
| US8987468B2 (en) | 2008-02-04 | 2015-03-24 | The Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives |
| CN104224703A (zh) | 2008-09-25 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀的液体配制品 |
| MX2011003751A (es) | 2008-10-08 | 2011-04-27 | Cephalon Inc | Procesos para preparar bendamustina. |
| WO2010075542A1 (en) | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
| ME02254B (me) * | 2009-01-23 | 2015-12-31 | Euro Celtique Sa | Derivati hidroksamske kiseline |
| AU2010217297A1 (en) | 2009-02-25 | 2011-10-20 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| WO2011017448A1 (en) | 2009-08-05 | 2011-02-10 | The Trustees Of The University Of Pennsylvania | Use of histone deacetylase inhibitors for treatment of autoimmune diseases |
| CN101928234B (zh) | 2010-01-15 | 2012-12-12 | 北京欧凯纳斯科技有限公司 | 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法 |
| WO2011130689A1 (en) | 2010-04-15 | 2011-10-20 | Tracon Pharmaceuticals, Inc. | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
| US9889147B2 (en) | 2010-04-16 | 2018-02-13 | Cellact Pharma Gmbh | Analogues of etoposide for the treatment of tumours |
| JO3659B1 (ar) | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| US8748470B2 (en) | 2011-03-17 | 2014-06-10 | The University Of Chicago | Methods for treating ovarian cancer by inhibiting fatty acid binding proteins |
| UA110853C2 (uk) | 2011-09-13 | 2016-02-25 | Фармасайклікс, Інк. | Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування |
| CN102993102B (zh) | 2011-09-16 | 2016-08-24 | 杭州民生药业有限公司 | [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法 |
| EP2758052B9 (en) | 2011-09-18 | 2019-03-27 | Euro-Celtique S.A. | Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide |
| ES2616242T3 (es) | 2011-09-28 | 2017-06-12 | Euro-Celtique S.A. | Derivados de mostaza de nitrógeno |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| US10335494B2 (en) | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
| NZ630314A (en) | 2014-02-18 | 2016-03-31 | Celgene Corp | Combination therapy for hematological malignancies |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| CN107438436A (zh) | 2014-12-05 | 2017-12-05 | 摩德纳和雷焦艾米利亚大学 | 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合 |
| JP2016109634A (ja) | 2014-12-09 | 2016-06-20 | 株式会社安川電機 | エンコーダ及びエンコーダ付きモータ |
| US20180311215A1 (en) | 2015-10-20 | 2018-11-01 | Hangzhou TINO Pharma Co., Ltd. | Pharmaceutical composition and preparation method therefor |
| US20180098969A1 (en) | 2016-10-11 | 2018-04-12 | Purdue Pharmaceutical Products L.P. | Hodgkin lymphoma therapy |
| WO2018068832A1 (en) | 2016-10-11 | 2018-04-19 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| EP3897626B1 (en) | 2018-12-18 | 2025-09-10 | Mundipharma International Corporation Limited | Tinostamustine for treating multiple myeloma |
| US20240252472A1 (en) | 2023-01-25 | 2024-08-01 | Purdue Pharma L.P. | Combinations for treating cancer |
-
2014
- 2014-05-28 GB GBGB1409471.8A patent/GB201409471D0/en not_active Ceased
-
2015
- 2015-03-26 PT PT157151929T patent/PT3148529T/pt unknown
- 2015-03-26 UA UAA201613401A patent/UA121311C2/uk unknown
- 2015-03-26 ES ES15715192T patent/ES2897727T3/es active Active
- 2015-03-26 DK DK15715192.9T patent/DK3148529T3/da active
- 2015-03-26 SG SG11201609365UA patent/SG11201609365UA/en unknown
- 2015-03-26 SG SG10201810397SA patent/SG10201810397SA/en unknown
- 2015-03-26 AU AU2015266342A patent/AU2015266342B2/en active Active
- 2015-03-26 KR KR1020167035883A patent/KR102383794B1/ko active Active
- 2015-03-26 EP EP15715192.9A patent/EP3148529B1/en active Active
- 2015-03-26 CA CA2950374A patent/CA2950374C/en active Active
- 2015-03-26 JP JP2016569405A patent/JP6553092B2/ja active Active
- 2015-03-26 EA EA201692472A patent/EA037057B1/ru not_active IP Right Cessation
- 2015-03-26 CN CN201580029183.2A patent/CN106659712A/zh active Pending
- 2015-03-26 CN CN202010076119.2A patent/CN111467339A/zh active Pending
- 2015-03-26 EP EP21203542.2A patent/EP3998068A1/en not_active Withdrawn
- 2015-03-26 BR BR112016027048-7A patent/BR112016027048B1/pt active IP Right Grant
- 2015-03-26 MX MX2016015436A patent/MX376193B/es active IP Right Grant
- 2015-03-26 WO PCT/EP2015/056667 patent/WO2015180865A1/en not_active Ceased
- 2015-03-26 US US15/314,172 patent/US11419853B2/en active Active
- 2015-05-26 CA CA2950338A patent/CA2950338C/en active Active
- 2015-05-26 IL IL249231A patent/IL249231B/en unknown
- 2015-05-26 EP EP21188323.6A patent/EP3957307A1/en not_active Withdrawn
- 2015-05-26 JP JP2016569589A patent/JP2017518291A/ja active Pending
- 2015-05-26 KR KR1020167035176A patent/KR102451701B1/ko active Active
- 2015-05-26 SG SG11201609360WA patent/SG11201609360WA/en unknown
- 2015-05-26 SG SG10201810401RA patent/SG10201810401RA/en unknown
- 2015-05-26 UA UAA201613398A patent/UA122207C2/uk unknown
- 2015-05-26 US US15/314,162 patent/US20170151218A1/en not_active Abandoned
- 2015-05-26 CN CN201580027992.XA patent/CN106470696B/zh active Active
- 2015-05-26 TW TW104116783A patent/TWI724990B/zh active
- 2015-05-26 EA EA201692480A patent/EA035658B1/ru not_active IP Right Cessation
- 2015-05-26 WO PCT/EP2015/061571 patent/WO2015181156A1/en not_active Ceased
- 2015-05-26 MX MX2016015434A patent/MX382162B/es unknown
- 2015-05-26 AU AU2015266052A patent/AU2015266052B2/en active Active
- 2015-05-26 ES ES15726087T patent/ES2949222T3/es active Active
- 2015-05-26 EP EP15726087.8A patent/EP3148536B1/en active Active
- 2015-05-26 BR BR112016027041-0A patent/BR112016027041B1/pt active IP Right Grant
-
2016
- 2016-10-26 ZA ZA2016/07384A patent/ZA201607384B/en unknown
- 2016-10-31 ZA ZA2016/07488A patent/ZA201607488B/en unknown
- 2016-11-25 PH PH12016502354A patent/PH12016502354A1/en unknown
- 2016-11-25 PH PH12016502355A patent/PH12016502355B1/en unknown
- 2016-11-27 IL IL249229A patent/IL249229B/en active IP Right Grant
-
2018
- 2018-05-21 US US15/985,097 patent/US10406138B2/en active Active
-
2019
- 2019-07-22 US US16/517,936 patent/US20190343807A1/en not_active Abandoned
-
2020
- 2020-12-24 JP JP2020215170A patent/JP7274450B2/ja active Active
-
2021
- 2021-03-25 US US17/212,765 patent/US11559516B2/en active Active
-
2022
- 2022-07-27 US US17/874,621 patent/US12370177B2/en active Active
- 2022-12-22 US US18/086,958 patent/US12048688B2/en active Active
-
2024
- 2024-06-14 US US18/743,233 patent/US12403130B2/en active Active
-
2025
- 2025-07-28 US US19/282,681 patent/US20260232638A1/en active Pending
- 2025-08-27 US US19/311,058 patent/US20260102375A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106470696B (zh) | 用于治疗癌症的药物组合 | |
| US20120045524A1 (en) | Combination therapy with parp inhibitors | |
| JP2006503919A5 (enExample) | ||
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| JP2022533578A5 (enExample) | ||
| JP2019516711A5 (enExample) | ||
| JP2013525291A (ja) | 肝がんの治療に使用するための有機化合物 | |
| JP2015534578A5 (enExample) | ||
| JP2017518291A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2012512158A5 (enExample) | ||
| US20140093585A1 (en) | Parp inhibitors for the treatment of cipn | |
| CN102740851A (zh) | Pi3k抑制剂和mek抑制剂的组合 | |
| JP2015096544A5 (enExample) | ||
| CN102006875A (zh) | 吡铂和贝伐单抗治疗结直肠癌的用途 | |
| Doghman et al. | Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma | |
| JP2016525097A5 (enExample) | ||
| JP2016522202A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| JP2017518292A5 (enExample) | ||
| JP2009506054A5 (enExample) | ||
| CN115025090A (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| US20080146638A1 (en) | Combination therapy with parp inhibitors | |
| ES2956411T3 (es) | Combinaciones farmacéuticas | |
| JP2015514796A (ja) | ２から３０ｍｇ／ｋｇの範囲の用量で癌を治療するのに使用するためのデキサナビノールまたはこの誘導体 |